Orchid Pharma Intrinsic Value
Orchid Pharma (ORCHPHARMA) median intrinsic value is ₹320.00 from 4 valuation models (range ₹219–₹497), vs current price ₹546.60 — -41.5% downside (Trading Above Calculated Value), margin of safety -70.8%. For current market price and key ratios, visit ORCHPHARMA share price.
ORCHPHARMA Valuation Methods Summary — DCF, Graham Number & P/E
Orchid Pharma intrinsic value across 4 models vs current price ₹546.60 — upside/downside and value range per method. Browse ORCHPHARMA financial statements for revenue, profit, balance sheet and cash flow data.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| Book Value Method | asset | ₹496.86 | ₹447.17 - ₹546.55 | -9.1% | Book Value/Share: ₹248.43, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹320.00 | ₹288.00 - ₹352.00 | -41.5% | Revenue/Share: ₹160.00, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹218.64 | ₹196.78 - ₹240.50 | -60.0% | EBITDA: ₹36.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹218.64 | ₹174.91 - ₹262.37 | -60.0% | CF Growth: 5.0%, Discount: 15% |
ORCHPHARMA Intrinsic Value vs Market Price — All Valuation Models
Orchid Pharma fair value range ₹219–₹497 vs current market price ₹546.60 across 4 valuation models. Compare with ORCHPHARMA intrinsic value calculation to assess whether the stock is under or overvalued.
ORCHPHARMA Intrinsic Value Analysis — Undervalued or Overvalued?
Orchid Pharma median intrinsic value ₹320.00, current price ₹546.60 — Trading Above Calculated Value by 41.5%, margin of safety -70.8%.
What is the intrinsic value of ORCHPHARMA?
Based on our comprehensive analysis using 4 different valuation methods, the estimated intrinsic value of Orchid Pharma (ORCHPHARMA) is ₹320.00 (median value). With the current market price of ₹546.60, this represents a -41.5% variance from our estimated fair value.
The valuation range spans from ₹218.64 to ₹496.86, indicating ₹218.64 - ₹496.86.
Is ORCHPHARMA undervalued or overvalued?
Based on our multi-method analysis, Orchid Pharma (ORCHPHARMA) appears to be trading above calculated value by approximately 41.5%.
ORCHPHARMA Financial Health — Key Ratios vs Industry Benchmarks
Orchid Pharma financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 5.98 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | -1.9% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | -1.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.48x | Industry Standard: 1.0x+ | Below 0.5x | Measures asset utilization efficiency |
ORCHPHARMA Cash Flow Quality — Operating & Free Cash Flow
Orchid Pharma operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹19 Cr | ₹6 Cr | Positive Free Cash Flow | 7/10 |
| March 2024 | ₹126 Cr | ₹-30 Cr | Positive Operating Cash Flow | 6/10 |
| March 2023 | ₹18 Cr | ₹3 Cr | Positive Free Cash Flow | 7/10 |
| March 2022 | ₹93 Cr | ₹93 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹24 Cr | ₹24 Cr | Positive Free Cash Flow | 8/10 |